Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Joachim J. Gerloff"'
Autor:
Wolfgang Uhl, Stefan Zastrow, Manfred P. Wirth, Axel Heidenreich, Michael Zühlsdorf, Joachim J. Gerloff, Michael Laniado, Heinrich Lannert, Thierry Gil, Jürgen E. Gschwend, Giacomo G. Mordenti
Publikováno v:
European urology. 65(5)
Background EMD 525797 (DI17E6) is a deimmunized, humanized monoclonal immunoglobulin G2 antibody against the αv subunit of human integrins. Blocking αv integrins may be an effective strategy for inhibiting prostate cancer (PCa) metastasis. Objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6dbea60ff3a046e236d29bc08327b51
https://pubmed.ncbi.nlm.nih.gov/23838638
https://pubmed.ncbi.nlm.nih.gov/23838638
Autor:
Michael Laniado, Axel Heidenreich, M. Wirth, Jürgen E. Gschwend, Stefan Zastrow, Wolfgang Uhl, Michael Zühlsdorf, Thierry Gil, Heinrich Lannert, Joachim J. Gerloff
Publikováno v:
Annals of Oncology. 23:xi21
Background EMD 525797 is a humanized monoclonal IgG2 antibody specifically targeting av integrins involved in tumor progression. Methods The safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of EMD 525797 were assessed in metastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aba143443601e63b6a2b7f2ccfe512f6
https://doi.org/10.1016/s0923-7534(20)31972-4
https://doi.org/10.1016/s0923-7534(20)31972-4
Autor:
Wolfgang Uhl, Michael Laniado, Joachim J. Gerloff, Heinrich Lannert, Thierry Gil, Stefan Zastrow, Jürgen E. Gschwend, Michael Zuehlsdorf, Manfred P. Wirth, Axel Heidenreich
Publikováno v:
Journal of Clinical Oncology. 30:231-231
231 Background: EMD 525797 is a humanized monoclonal IgG2 antibody specifically targeting αv integrins involved in tumor progression. Methods: The safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of EMD 525797 were assessed in me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81982b298941c057809f3efb95ef91e8
https://doi.org/10.1200/jco.2012.30.5_suppl.231
https://doi.org/10.1200/jco.2012.30.5_suppl.231
Autor:
Wirth M; Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany. Electronic address: Manfred.Wirth@uniklinikum-dresden.de., Heidenreich A; Department of Urology, RWTH Aachen University, Aachen, Germany., Gschwend JE; Department of Urology, Technical University of Munich Klinikum Rechts der Isar, Munich, Germany., Gil T; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Zastrow S; Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Laniado M; Department of Urology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., Gerloff J; Merck KGaA, Darmstadt, Germany., Zühlsdorf M; Merck KGaA, Darmstadt, Germany., Mordenti G; Merck KGaA, Darmstadt, Germany., Uhl W; Merck KGaA, Darmstadt, Germany., Lannert H; Merck KGaA, Darmstadt, Germany.
Publikováno v:
European urology [Eur Urol] 2014 May; Vol. 65 (5), pp. 897-904. Date of Electronic Publication: 2013 Jun 06.